Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.

[1]  J. Robertson,et al.  Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. , 2003, European journal of cancer.

[2]  A. Milla-Santos,et al.  Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer: A Prospective, Randomized, Phase III Study , 2003, American journal of clinical oncology.

[3]  P. Goss.  Preliminary data from ongoing adjuvant aromatase inhibitor trials. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Mesiti,et al.  Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[6]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Lønning,et al.  Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Dirix,et al.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Coombes,et al.  Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. , 1999, European journal of cancer.

[12]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[13]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[14]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Paridaens,et al.  Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. , 1997, European journal of cancer.

[16]  F. Cavalli,et al.  First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Pitt,et al.  Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer , 1995, Breast Cancer Research and Treatment.